Cellectar director Andrew Gu files Form 3

Cellectar Biosciences, Inc. director Andrew Gu filed an initial Form 3, which is a required statement of beneficial ownership when someone becomes an insider.

Rhea-AI Filing Summary

Cellectar Biosciences, Inc. director Andrew Gu filed an initial Form 3, which is a required statement of beneficial ownership when someone becomes an insider. This filing lists his status as a director but shows no reported purchases, sales, or other transactions in Cellectar securities.

Key Figures

Reported buy transactions: 0 Reported sell transactions: 0 Net buy/sell direction: neutral

3 metrics

Reported buy transactions 0 Form 3 transaction summary

Reported sell transactions 0 Form 3 transaction summary

Net buy/sell direction neutral Form 3 transaction summary

Key Terms

Form 3, beneficial ownership, insider

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership regulatory

"initial statement of beneficial ownership when someone becomes an insider"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

insider regulatory

"required statement of beneficial ownership when someone becomes an insider"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Cellectar Biosciences (CLRB) Form 3 for Andrew Gu show?

The Form 3 for Cellectar Biosciences director Andrew Gu reports his initial beneficial ownership status as an insider. It lists him as a director and shows no reported purchases, sales, or other transactions in Cellectar Biosciences securities at the time of this filing.

Who is the reporting person on the Cellectar Biosciences (CLRB) Form 3?

The reporting person is Andrew Gu, identified as a director of Cellectar Biosciences, Inc. The Form 3 indicates his insider status under SEC rules. It does not include any reported transactions, only his role and that this is an initial ownership statement.

Does the Cellectar Biosciences (CLRB) Form 3 report any stock transactions?

No, this Cellectar Biosciences Form 3 for director Andrew Gu reports zero buy, sell, gift, exercise, or other transactions. It functions purely as an initial ownership statement required when someone becomes an insider, without detailing any specific trades.

Why is a Form 3 important for Cellectar Biosciences (CLRB) investors?

Form 3 establishes a baseline record of an insider’s beneficial ownership when they assume a reportable role. For Cellectar Biosciences, Andrew Gu’s Form 3 confirms his director status and sets the reference point for any future Form 4 or Form 5 insider trading reports.

What do the transaction counts on Andrew Gu’s Cellectar (CLRB) Form 3 indicate?

The transaction summary on Andrew Gu’s Form 3 shows zero buys, sells, exercises, gifts, or other dispositions. This means the filing does not reflect any recent insider trading activity and instead serves solely as an initial registration of his insider position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 05:00 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Gu Andrew

(Last) (First) (Middle)

C/O CELLECTAR BIOSCIENCES, INC.

100 CAMPUS DRIVE

(Street)

FLORHAM PARK NEW JERSEY 07932

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/18/2026

3. Issuer Name and Ticker or Trading Symbol
Cellectar Biosciences, Inc. [ CLRB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Christina Blakley, Attorney-in-fact for Andrew Gu	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)